Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Coronary Artery Stenting · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Coronary Artery Stenting | DEVICE | Initial implant of drug eluting stent (zotarolimus) |
Inclusion Criteria: 1. Patient is at least 18 years old 2. Patient is an acceptable candidate for percutaneous coronary intervention and emergent coronary artery bypass graft surgery 3. Patient has clinical evidence of ischemic heart disease or a positive functional study 4. Female patients of chil...
Coronary Artery Stenting is used for the treatment of Coronary Artery Disease. It is an investigational therapy being developed by Medtronic plc. The therapy is currently in Phase 1 clinical development, with one completed clinical trial involving 139 participants in Australia.
Coronary Artery Stenting is being developed by Medtronic plc, a medical device company traded on the New York Stock Exchange under the ticker symbol MDT. The therapy is currently in Phase 1 clinical development for the treatment of Coronary Artery Disease.
Coronary Artery Stenting is in Phase 1 clinical development. It is an investigational therapy for Coronary Artery Disease and has not yet been approved by regulatory authorities. One Phase 1 clinical trial has been completed, with no active trials currently ongoing.
Coronary Artery Stenting has one completed clinical trial, the Medtronic RESOLUTE Clinical Trial (NCT00248079). This Phase 1 study enrolled 139 participants with Coronary Artery Disease in Australia. The trial was uncontrolled and not randomized or double-blinded.
Coronary Artery Stenting is the investigational therapy evaluated in the Medtronic RESOLUTE Clinical Trial, identified by the clinical trial identifier NCT00248079. This Phase 1 study was conducted in Australia and enrolled 139 participants with Coronary Artery Disease.